相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PROTAC targeted protein degraders: the past is prologue
Miklos Bekes et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
Kunle Odunsi et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
Michael Weller et al.
NEURO-ONCOLOGY (2021)
Combination immunotherapy strategies for glioblastoma
Hok Yee Chan et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor
Yunze Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe et al.
CELL CHEMICAL BIOLOGY (2021)
NER-factor DDB2 regulates HIF1α and hypoxia-response genes in HNSCC
Prashant Bommi et al.
ONCOGENE (2020)
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
Mingxing Hu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Assays and technologies for developing proteolysis targeting chimera degraders
Xingui Liu et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Lijie Zhai et al.
FRONTIERS IN IMMUNOLOGY (2020)
Development and Characterization of a Wee1 Kinase Degrader
Zhengnian Li et al.
CELL CHEMICAL BIOLOGY (2020)
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma
Erik Ladomersky et al.
FRONTIERS IN PHARMACOLOGY (2019)
Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats
Yan Zhang et al.
DRUG METABOLISM AND DISPOSITION (2019)
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges
Scott D. Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
Kenneth J. Fraunhoffer et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2019)
SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
Michael J. Roy et al.
ACS CHEMICAL BIOLOGY (2019)
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyI)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (VH298)
Pedro Soares et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
Micah T. Nelp et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer
Ari J. Rosenberg et al.
Oncotarget (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression
Abhishek Mangaonkar et al.
SCIENTIFIC REPORTS (2017)
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma
Lijie Zhai et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
Straightforward synthesis of a novel ring-fused pyrazole-lactam and in vitro cytotoxic activity on cancer cell lines
G. Bertuzzi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
The role of IDO in brain tumor immunotherapy
Lijie Zhai et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Targeting Tregs in malignant brain cancer: overcoming IDO
Derek A. Wainwright et al.
FRONTIERS IN IMMUNOLOGY (2013)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors
Derek A. Wainwright et al.
NEURO-ONCOLOGY (2011)
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Sergei I. Grivennikov et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
David J. Chung et al.
BLOOD (2009)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Label-Free Detection of Biomolecular Interactions Using BioLayer Interferometry for Kinetic Characterization
Joy Concepcion et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2009)
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
Tomoko Inaba et al.
GYNECOLOGIC ONCOLOGY (2009)
Microcalorimetry of biological macromolecules
Peter L. Privalov et al.
BIOPHYSICAL CHEMISTRY (2007)
The two NF-κB activation pathways and their role in innate and adaptive immunity
G Bonizzi et al.
TRENDS IN IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
